Author: Wayne Winegarden

Home > Articles posted by Wayne Winegarden (Page 4)

December 9, 2020 Briefs, Price and Costs

Tearing down drug “rebate walls” that increase patient costs and block access to cheaper and often more effective medications would increase competition, lower out-of-pocket costs, and improve health outcomes, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. Click to download the brief “America’s patients are harmed because they do not benefit from large, fast-growing rebates when purchasing their medicines,” writes the brief’s author, Dr. Wayne Winegarden, director of PRI’s Center...

September 29, 2020 Briefs, Price and Costs

A new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute found that reforms mandating drug rebates benefit patients rather than payers would lower overall health care costs and help patients with expensive out-of-pocket drug costs. Click here to download the brief “Ironically, the current drug concession system is raising patient costs,” write the briefs authors, Wayne Winegarden and Robert Popovian. “Mandating that all drug concessions must benefit the patients purchasing the medicines is a...

September 28, 2020 Blog, Coronavirus-Alternate2

Politicians continue perpetuating the myth that drug price controls are the necessary cure for the country’s healthcare affordability problems. Whether it is Speaker Pelosi’s “The Lower Drug Costs Now Act”, or President Trump’s Most Favored Nation (MFN) and Drug Importation Executive Orders, these policies are destined to fail. Undoubtedly, there are problems with the drug pricing system that harms patients, and reforms that fix these problems are urgently needed. But, adopting the ill-fated price controls that are implemented in other industrialized countries will create new...

September 15, 2020 Policy Proposals

President Trump and senior advisor Jared Kushner claim that the most favored nation executive order signed by the President over the weekend is necessary for drug pricing because “the U.S. shouldn’t pay more than other European countries for the same treatments.” This policy will make things worse, not better. If the president and his son-in-law applied their flawed logic consistently, then there is an even greater economic disparity that requires fixing. People living in Manhattan or San Francisco are paying more than other...

September 15, 2020 Industry Trends

Pacific Research Institute senior fellow and economist Dr. Wayne Winegarden talks free market energy, California rolling power blackouts, and optimistic solutions to energy policy on The Roth Effect with Carol Roth. Winegarden also discusses his recent studies that challenge green energy, fracking, electric vehicles, and more. [embed]https://mp3.ricochet.com/2020/09/Roth_Effect_66.mp3[/embed]...

September 3, 2020 Price and Costs

Title: AB 72 brief analyzes impact of medical billing reform law that's had bad consequences for patients and practitioners By Sarah Downey, Northern California Record A new policy brief about the impact of California AB 72 finds that the law – designed to alleviate surprise medical billing – while well-intentioned also has unintended consequences that have increased medical costs and affected quality of care. The Pacific Research Institute (PRI) brief, “The Menace of Medical Rate Setting: The Case of California’s AB 72,” is...

August 19, 2020 Briefs, Price and Costs

SAN FRANCISCO – California’s surprise medical billing law (Assembly Bill 72) – which imposes price controls on the rates out-of-network physicians can charge at in-network facilities – is hurting patients with lower quality care, reduced access, and higher health care system costs, finds a new brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the brief “California’s surprise medical billing law has created unintended consequences that are increasing healthcare costs and...

August 18, 2020 Coronavirus

PRI's Dr. Wayne Winegarden joins the Pegasus Institute to discuss the danger of price controls in health care including hurting rural health care providers and threatening the already thin margins many hospitals operate on. Winegarden also talks about the impact of the coronavirus and COVID-19. Pegasus Institute · The Problem With Price Controls in Healthcare with Wayne Winegarden of Pacific Research Institute...

August 14, 2020 Coronavirus

The value of innovative medicines has absolutely nothing to do with its cost of production. Yet, not only does this myth persist, it appears to be growing. In the latest example, an article in the Journal of Virus Eradication claims that drugs being repurposed in the hopes they might be effective treatments for Covid-19, such as remdesivir and sofosbuvir, could be profitable at very low costs. How do the authors come up with this conclusion? They claim that the costs of production range between...

July 31, 2020 Issues, Price and Costs

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text css=".vc_custom_1596236774320{padding-right: 40px !important;}"]DOWNLOAD THE PDF In October 2019, the Center for Medical Economics and Innovation at the Pacific Research Institute, under the direction of Dr. Wayne Winegarden, released its second study documenting the savings potential enabled by biosimilars. Biosimilars are medicines manufactured in, or derived from, biological sources that are developed to be similar to FDA-approved reference products. Biosimilars are only approved to compete in nine biologic drug classes in the U.S.,...

July 24, 2020 Issues, Policy Proposals, Price and Costs

President Reagan famously said, “the nine most terrifying words in the English language are: I’m from the Government and I’m here to help”. It is time for President Trump to learn this wisdom. Along with Speaker Pelosi, Senator Sanders, and Representative Ocasio-Cortez, President Trump seems to believe that giving the government the authority to impose price controls on medicines will help patients. And, following the signing ceremony on Friday, he is now officially trying to make government price controls a reality. Of...

July 20, 2020 Policy Proposals

The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, these are just two of the many treatments that are showing great potential for patients. There are also multiple vaccines that are advancing at light speed while still maintaining the necessary safety protocols....

May 21, 2020 Issues, Price and Costs

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text css=".vc_custom_1590107672986{padding-right: 40px !important;}"]DOWNLOAD THE PDF In October 2019, the Center for Medical Economics and Innovation at the Pacific Research Institute, under the direction of Dr. Wayne Winegarden, released its second study documenting the savings potential enabled by biosimilars. Biosimilars are medicines manufactured in, or derived from, biological sources that are developed to be similar to FDA-approved reference products. Biosimilars are only approved to compete in nine biologic drug classes in the U.S....

May 15, 2020 Innovation, Issues

Medical innovations do not happen overnight. Whether it is gene therapies, new vaccines, or cutting-edge medical equipment, developing innovative medical products is a risky venture. It also takes time, lots of financial resources, and most importantly, human ingenuity. Developing new drugs, for instance, can take between 10 and 15 years. Now, more than ever, it is imperative that our regulatory framework encourages innovation and protects the intellectual property that makes innovation possible. Otherwise, the medical advancements we desperately need will cease....

May 11, 2020 Coronavirus, Issues, Price and Costs, Value

There they go again. In the midst of the race for an effective COVID-19 treatment the Institute for Clinical and Economic Review (ICER) has performed an incomplete analysis of remdesivir in order to produce a cost estimate that is, by definition, precisely wrong. Remdesivir, produced by Gilead Sciences Inc., is an experimental antiviral medication that did not work as hoped to treat Hepatitis C, but is showing promise as a treatment for viruses such as SARS and COVID-19. If ICER’s analysis were...

May 8, 2020 Blog, Issues, Policy Proposals

It was not long ago that the economy’s rising tide was supporting state budgets across the country. As the Pew Charitable Trusts noted, widespread economic prosperity was supporting tax revenue growth and creating budget surpluses. When times are good, saving money is not always a priority in state capitols. But, times are no longer good, and saving money is now a top policy priority. The carnage is not contained to state budgets either. Businesses large and small are losing money, families are struggling...

April 30, 2020 Blog, Coronavirus

Forcing a restructuring of the current pharmaceutical supply chain is a terrible idea. Yet, as a recent Wall Street Journal editorial exemplifies, there is growing support for this ill-considered policy. And, these proposals are not simply mere academic musings. The Trump Administration may implement an Executive Order that would turn this idea into actual policy. Congress, not to be outdone, is also considering several proposals that would force federal agencies to purchase drugs and medical supplies exclusively from U.S. suppliers. If implemented, these “Buy...

April 6, 2020 Blog, Coronavirus

The Centers for Disease Control and Prevention (CDC) has issued guidance for healthcare facilities in response to the COVID-19 virus including asking all U.S. healthcare facilities to “explore alternatives to face-to-face triage and visits.” The CDC has issued this recommendation to help contain the spread of the virus, protect healthcare workers from unnecessary exposure, and protect the health of patients who do not require face-to-face medical visits (particularly patients with underlying health issues including those with heart, kidney and weakened immune systems). In light...

March 31, 2020 Blog, Coronavirus

Private pharmaceutical companies and the National Institutes of Health have outdone themselves. Thanks to the funding provided by the NIH, a Phase 1 clinical trial for a COVID-19 vaccine  is underway. In separate efforts, Inovio, Sanofi, Vaxart, GlaxoSmithKline, and Johnson & Johnson are all developing potential vaccines. In total, “about 35 companies and academic institutions are racing to create a vaccine, at least four of which already have candidates they have been testing in animals. The first of these – produced by Boston-based...

March 17, 2020 Blog, Policy Proposals

The costs of economic fallacies are magnified during times of crises. Unfortunately, the Trump Administration’s trade fallacies are not only threatening our economic well-being, they are now putting people’s lives at risk. It is becoming politically incorrect to recognize that the expansion of international trade has helped Americans live better, more prosperous, lives. But, that does not change the reality that Americans benefit greatly from the global economy. As Dr. Arthur Laffer explained in a 2007 speech on the pillars of Reaganomics at the...